Expression analysis of miR-223 in plasma of patients with non-small cell lung cancer and other obstructive lung diseases

Conclusions: MiR-223 is differently expressed in plasma from LC, COPD and asthma patients. In order to ascertain its role as biomarker for discrimination of patients analysis of enlarged sampling is necessary. Funded by Medical University, Sofia, contract Nr. 90/2016.

Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Marinova, D., Kachakova, D., Dimitrova, D., Lilov, A., Mekov, E., Mihailov, M., Giragosyan, S., Slavova, Y., Kostadinov, D., Youroukova, V., Petkov, R., Mitkova, A., Kaneva, R., Mitev, V. Tags: Lung Cancer Source Type: research